GLP-1 Weight Loss Trial Outcomes

The FDA-approved brand-name semaglutide and tirzepatide products were each evaluated in pivotal clinical-trial programs reviewed by the FDA as part of their approval. Those published outcomes were generated using the FDA-approved reference products. Compounded versions are not FDA-evaluated, and brand-product trial outcomes should not be assumed to apply to them.

Weight change is usually tracked over a course of consistent dosing, with periodic check-ins to review tolerance and adjust the plan. Your Weight Method provider sets expectations based on your individual clinical profile rather than on brand-product trial figures.

Clinical-trial outcomes were generated using the FDA-approved brand-name products. Compounded medications are not FDA-evaluated, and brand-product trial outcomes should not be assumed to apply to compounded versions. Individual results vary.

Published extension studies of the brand-name products reported some weight regain after discontinuation. Maintaining results long-term typically involves lifestyle changes and, in some cases, continued treatment.

Starting BMI, adherence to the prescribed schedule, diet, physical activity, and individual metabolism all influence response. Your Weight Method provider will set expectations based on your individual clinical profile.